Shanghai Haohai Biological Technology Co., Ltd. (6826.HK / 688366.SH)

Deep-Dive Research Report

Sector: Healthcare - Biomaterials & Medical Devices Listings: HKEX H-shares (6826.HK, since April 2015) + Shanghai STAR Market A-shares (688366.SH, since October 2019) Report date: 2026-06-14 Reporting currency: RMB (HK$ for H-share buybacks/dividends where noted)

A note on the financial-disclosure regime used throughout this report. Haohai is a Chinese A+H dual-listed issuer. It does not host Western-style earnings calls with published transcripts. Instead it files quarterly reports (Q1, interim/H1, Q3, annual) on both the SSE and HKEX, supplemented by occasional "Investor Relations Activity Records" (投资者关系活动记录表) that document management Q&A. The five "reporting periods" used in Sections 7 and 9 are those quarterly disclosures and IR records. Per the prompt's no-financials rule, this report avoids absolute revenue and profit figures and instead describes direction, growth rates, and mix; Section 10 (capital return) and Section 11 (insider activity) carry the specific numbers the prompt mandates.

SECTION 1: WHAT THE COMPANY DOES

Haohai makes a small number of biological molecules - principally hyaluronic acid (sodium hyaluronate) and collagen - and turns them into high-value medical products that get injected into people: into faces to smooth wrinkles, into knees to lubricate arthritic joints, into eyes during cataract surgery, and into surgical wounds to stop bleeding and prevent internal tissues from sticking together. It also manufactures the hardware of eye surgery - intraocular lenses (the artificial lens implanted when a cataract is removed) - and the raw polymer materials that the world's contact-lens and lens makers buy to make their own products.

The simplest way to understand Haohai is this: it is a hyaluronic-acid and biomaterials house that learned to sell the same underlying chemistry into four different regulated medical markets, each with its own sales force, regulatory pathway, and competitive set.

Founding story. Haohai was incorporated in Shanghai on 24 January 2007 by a husband-and-wife team, Jiang Wei (蒋伟) and You Jie (游捷), who remain the controlling shareholders today (roughly 28.5% and 17.3% respectively). The founding move was not invention but consolidation: in 2007 the company rolled up three established HA manufacturers - the Songjiang factory, Shanghai Jianhua, and Qisheng Biological - and in doing so inherited mature positions in ophthalmic viscoelastics, orthopedic joint injections, and surgical anti-adhesion products. From the start, then, Haohai was an acquisitive aggregator of regulated biomaterials franchises rather than a single-product start-up. That DNA matters: the medical-aesthetics business, the contact-lens-materials business (Contamac), and parts of the intraocular-lens business all arrived through acquisition.

Two listings shaped its capital strategy. The 2015 Hong Kong IPO (roughly HK$2.3 billion raised) funded international expansion, including the 2017 purchase of a 70% stake in the UK's Contamac, the world's largest independent maker of contact-lens and intraocular-lens materials. In October 2019 Haohai became the first "H-share + STAR Market" biopharmaceutical company in China, pricing its Shanghai A-shares at what was then the highest STAR-Market debut price (RMB 89.23).

Core value proposition. Haohai sells trust in injectable and implantable biomaterials. For a dermatologist injecting filler, an ophthalmic surgeon implanting a lens, or an orthopedist treating an arthritic knee, the product must be sterile, biocompatible, predictable, and backed by Chinese regulatory approval (NMPA Class III device clearance). Haohai's pitch is that it owns the upstream chemistry (HA fermentation and cross-linking, collagen processing, lens-material polymers) and the downstream NMPA approvals across multiple specialties, so it can offer a domestic, regulator-cleared alternative to imported brands at lower price points.

What makes it hard to replicate. The barrier is not the molecule - hyaluronic acid is widely produced - but the combination of (1) cross-linking and purification know-how that determines how long a filler lasts and how safe it is, (2) a Class III NMPA registration for each specific product and indication, which takes years and clinical trials, and (3) a specialty sales force that calls on hospitals and aesthetic clinics. Haohai's newest flagship filler, "Haimei Yuebai" (海魅月白), illustrates the point: it is China's first approved organically cross-linked HA filler, using the essential amino acid lysine as the cross-linker instead of the conventional chemical agent BDDE, a formulation pitched on longer-term safety. Getting that approved (NMPA Class III, July 2024) took years of development.

SECTION 2: BUSINESS SEGMENTS

Haohai runs four core segments. The approximate FY2025 revenue mix is medical aesthetics ~42%, ophthalmology ~33%, orthopedics ~13%, and anti-adhesion & hemostasis ~12% (derived from disclosed sub-segment figures; treat as approximate). Medical aesthetics overtook ophthalmology as the largest segment around 2023.

2.1 Medical Aesthetics and Wound Care (~42% of revenue)

What it does. This is the face-and-skin business: dermal fillers injected to smooth wrinkles and add volume, plus epidermal-repair products and aesthetic energy devices (radiofrequency and laser equipment). The HA filler line is structured as a four-generation good-better-best ladder:

• Haiwei (海薇) - first-generation HA filler, entry price (~RMB 500-1,000 per injection)
• Jiaolan (姣兰) - second-generation, mid-tier (~RMB 2,000-4,000)
• Haimei (海魅) - third-generation, premium (~RMB 11,000-13,000)
• Haimei Yuebai (海魅月白) - fourth-generation, organically (lysine) cross-linked, the newest premium product approved July 2024

Around the fillers sit a genetic-engineering epidermal-repair product (an external EGF, epidermal growth factor, holding roughly 27% of its wound-care niche) and a distributed/owned portfolio of RF and laser aesthetic devices.

Core capability. Cross-linking chemistry. The difference between a RMB 500 filler and a RMB 12,000 filler is how the HA chains are linked - which determines longevity, smoothness, and the risk of the dreaded "bun face" (馒化脸) over-filled look. Haimei Yuebai's lysine cross-linker and its claim to block the enzyme (hyaluronidase) that degrades HA are the technical edge management is betting on.

Why it is separate. Different customer (private aesthetic clinics, not hospitals), different sales motion (brand and KOL-driven, marketed on Douyin and Xiaohongshu), and a consumer-discretionary demand curve utterly unlike the reimbursed-medical demand of the other three segments.

Competitive position. This is the most contested segment. Haohai competes against Imeik (爱美客), whose "Hi-Body"/Hai Ti (嗨体) dominates the mid-to-high market, and Bloomage Biotech (华熙生物), plus imported premium brands (Allergan/AbbVie's Juvéderm). Haohai is a credible number-three-ish domestic player with a genuine premium product, but it does not have Imeik's margin profile or brand recall.

Role in the group. The designated growth engine. When management talks about the future, they talk about Haimei Yuebai ramping.

2.2 Ophthalmology (~33% of revenue)

What it does. Three sub-businesses: (1) ophthalmic viscoelastic devices (OVDs) - the HA gel surgeons inject into the eye to protect tissue during cataract surgery, where Haohai has been the Chinese market leader for 17 consecutive years (~47% share); (2) intraocular lenses (IOLs) - the artificial lens implanted after the cataract is removed, spanning hydrophobic, hydrophilic, aspheric, and increasingly toric (astigmatism) and multifocal designs; and (3) optometry/vision-correction - orthokeratology ("OK") lenses for myopia control, contact-lens products, and the upstream lens-materials business via Contamac, plus a developing eye-drop pharmaceutical line (sodium hyaluronate eye drops approved March 2024; pipeline bimatoprost, moxifloxacin, lidocaine gel, and an artificial vitreous body).

Core capability. Vertical integration into lens materials. Through Contamac (the world's largest independent contact/IOL material maker, and uniquely able to make both in one facility - its "Optimum Infinite" gas-permeable material won FDA clearance in 2019), Haohai owns the polymer feedstock that competitors must buy. Combined with 17 years of OVD market leadership, this is a deep, defensible franchise.

Why it is separate. Hospital-based, surgeon-driven, and increasingly governed by government volume-based procurement (VBP). Entirely different regulatory and pricing dynamics from consumer aesthetics.

Competitive position. OVDs: domestic leader. IOLs: caught in the crossfire of national VBP. Haohai competes with global majors - Alcon, Johnson & Johnson Vision, Bausch + Lomb, Carl Zeiss, HOYA, STAAR - and rising domestic players such as Eyebright Medical (爱博医疗). The November 2023 national IOL procurement, in which Alcon won bids at aggressive prices, compressed unit economics across the board.

Role in the group. The cash cow under pressure - historically the anchor, now the segment management is defending through cost re-engineering (a new hydrophobic molding process approved June 2023) and premiumization (toric/multifocal IOLs).

2.3 Orthopedics (~13% of revenue)

What it does. Sodium-hyaluronate joint-cavity viscosupplements - HA injected into arthritic joints (mainly knees) to restore lubrication and cushioning - often combined with medical chitin. Haohai is China's largest manufacturer here, market leader for roughly a decade (~50% share in 2024), and the only domestic supplier offering the complete 2ml / 2.5ml / 3ml range.

Core capability. Scale and a full-size-range registration in a product class where each dosage size is a separate NMPA approval. Combining HA with chitin is a differentiator versus single-component injections.

Why it is separate. Orthopedic clinics/hospitals, reimbursed-medical demand, and a different regulatory file from the eye and aesthetics products despite sharing the HA molecule.

Competitive position. Domestic share leader; global reference competitors include Anika Therapeutics (Monovisc/Orthovisc), Bioventus/Sanofi (Synvisc, Supartz), and Bioventus's Durolane. Within China the risk is the same VBP dynamic that hit IOLs spreading into joint injections.

Role in the group. A steady cash cow - high share, modest growth, exposed to procurement policy.

2.4 Surgical Anti-Adhesion and Hemostasis (~12% of revenue)

What it does. Products surgeons use inside the body during operations: anti-adhesion agents (HA/chitosan barriers that stop internal tissues from sticking together as they heal), a medical collagen sponge, and a porcine-derived fibrin sealant/adhesive for hemostasis. Haohai is China's largest surgical anti-adhesion maker, leader for 17 consecutive years (~29% share).

Core capability. Biomaterials breadth - collagen and chitosan processing alongside HA - and a long-tenured NMPA franchise across multiple surgical-consumable SKUs.

Why it is separate. Sold into operating theatres across many surgical specialties; a hospital-procurement, surgeon-preference business distinct from the others.

Competitive position. Domestic leader against global names (Ethicon/J&J, Baxter, Integra, FzioMed, Anika) and domestic peers (Singclean, Yishengtang). The most defensible, least-glamorous segment.

Role in the group. The quiet cash cow - stable share, stable demand from rising surgical volumes.

SECTION 3: PRODUCTS AND BUSINESS DETAIL

The full product catalogue.

Medical aesthetics: Haiwei (1st-gen HA filler), Jiaolan (2nd-gen), Haimei (3rd-gen), Haimei Yuebai (4th-gen, lysine organic cross-linked, NMPA Class III July 2024); an external EGF epidermal-repair product (genetic-engineering preparation, ~27% niche share); and a range of radiofrequency and laser aesthetic devices.

Ophthalmology: sodium-hyaluronate ophthalmic viscoelastic devices (market leader); a full intraocular-lens portfolio (hydrophobic, hydrophilic, aspheric, toric, multifocal, plus a new-type artificial vitreous body in development); orthokeratology (OK) lenses; contact lenses; sodium-hyaluronate eye drops (approved March 2024); and a pharmaceutical eye-drop pipeline (bimatoprost, moxifloxacin HCl, lidocaine gel). Via Contamac: Optimum-series gas-permeable contact-lens materials and IOL polymer materials sold globally.

Orthopedics: sodium-hyaluronate intra-articular injections in 2ml / 2.5ml / 3ml, some combined with medical chitin.

Anti-adhesion & hemostasis: HA and chitosan anti-adhesion barriers, medical collagen sponge, porcine-derived fibrin sealant/adhesive.

Technical specifications that matter. Every flagship product is an NMPA Class III medical device - the highest-risk regulatory class in China, requiring clinical trials and multi-year review. The defensible know-how is concentrated in (a) HA fermentation and the cross-linking step that sets filler longevity and safety (Yuebai's lysine cross-linker and hyaluronidase-blocking claim are the headline innovation), (b) IOL manufacturing, where Haohai's June-2023-approved hydrophobic molding process lowers cost versus traditional turning/milling, and (c) Contamac's ability to produce both contact-lens and IOL materials in a single qualified environment, an industry rarity.

Manufacturing and geography. Core biomaterials manufacturing is China-based (Shanghai/Songjiang heritage plants from the 2007 roll-up). Lens-material manufacturing sits in the UK at Contamac, giving Haohai a genuinely global footprint in that one niche. The customer base is overwhelmingly Chinese domestic for the medical products, with Contamac's materials exported worldwide.

Notable milestones. 2007 founding roll-up of three HA makers; 2015 Hong Kong IPO; 2017 Contamac acquisition (70%); 2019 record-priced STAR-Market listing; June 2023 hydrophobic-IOL molding process approval; March 2024 sodium-hyaluronate eye-drop approval; July 2024 Haimei Yuebai fourth-generation filler approval - the single most important recent product event.

SECTION 4: CUSTOMERS

Who buys, by segment. The buying relationship differs sharply across the four segments, which is the whole reason they are run separately.

Medical aesthetics sells to private aesthetic clinics and dermatology practices. The economic buyer is the clinic owner/injector; the decision criteria are brand pull with end-consumers, product safety reputation, longevity of result, and margin to the clinic. The "sales cycle" is really a marketing cycle - demand is created with consumers on Douyin and Xiaohongshu, then pulled through clinics. Because China restricted online medical-aesthetic advertising content, Haohai shifted spend to offline academic conferences (conference expense rose ~108% in 2023). Switching costs are low - clinics stock multiple brands - so this is a brand-and-efficacy contest, not a lock-in business.

Ophthalmology (OVD, IOL) sells to hospitals and eye-surgery centres. The buyer is increasingly the government, through volume-based procurement: provinces/national bodies run tenders, and winning a bid grants volume in exchange for a steep price cut. Surgeon preference still matters for premium IOLs not yet under hard VBP. Switching costs here are real at the procurement level - a lost tender means lost volume for the contract period - which cuts both ways.

Orthopedics and anti-adhesion sell to hospitals through clinical channels and tenders. The decision-makers are physicians and hospital procurement; criteria are clinical track record, NMPA registration breadth (full size range), and price. Long incumbency (a decade-plus of market leadership) creates familiarity-based stickiness with surgeons.

Concentration. No single end-customer dominates; demand is fragmented across thousands of clinics and hospitals. The more relevant concentration is channel and policy: a meaningful share of ophthalmology and orthopedics revenue is exposed to a handful of government procurement decisions. The Q3 2025 disclosure also flagged a working-capital concentration - accounts receivable running at roughly 71% of trailing net profit - a sign that hospital and distributor payment terms are stretching.

Contract structure. A mix of distributor relationships, hospital supply, tender-based volume awards (ophthalmology/orthopedics), and clinic-level spot/repeat purchasing (aesthetics). The aesthetics revenue is the least contractually predictable (consumer-discretionary), while VBP-awarded volumes give medium-term visibility at lower prices.

SECTION 5: COMPETITIVE LANDSCAPE

Haohai is unusual in that it competes in four different industries, each with a different competitive structure. It is a domestic market-share leader in three of them (OVDs, orthopedic viscosupplements, surgical anti-adhesion) and a challenger in the fourth and most lucrative (premium aesthetics fillers).

Medical aesthetics. The toughest arena. Imeik is the clear domestic profit leader, with a dominant mid-to-high filler franchise and far higher margins. Bloomage Biotech is the vertically integrated HA giant (raw material through finished consumer products) with the strongest brand recall. Imported premium brands (AbbVie/Allergan Juvéderm) anchor the top. Haohai competes on its premium fourth-generation product (Yuebai) and a full price ladder, but it is the number-three-class player here, not the leader, and 2025 saw its filler revenue fall sharply (down ~23% year-on-year) as consumer demand weakened and price competition intensified.

Ophthalmology. OVDs: Haohai leads China. IOLs: a genuinely global fight against Alcon, J&J Vision, Bausch + Lomb, Carl Zeiss, HOYA and STAAR, with domestic challenger Eyebright Medical rising. VBP has commoditized the base of the IOL market; Haohai is defending with cost-down manufacturing and premium toric/multifocal designs.

Orthopedics. Haohai is the domestic share leader (~50%) in joint viscosupplements; the relevant global names (Anika, Bioventus/Sanofi) are reference competitors more than direct China threats. The forward risk is policy (VBP) not a rival.

Anti-adhesion & hemostasis. Haohai leads China (~29%) against global majors (Ethicon, Baxter, Integra, FzioMed, Anika) and domestic peers (Singclean, Yishengtang). The most defensible position in the group.

Barriers to entry. Moderate-to-high and segment-specific: NMPA Class III registration (years, clinical trials), cross-linking/biomaterials process know-how, full-size-range registrations, and incumbent surgeon relationships. These barriers are real but they do not protect pricing once a category enters VBP - the government can compress margins regardless of how strong the moat looks.

Structural shifts. Three are reshaping the landscape: (1) VBP rolling category by category through the device industry, structurally lowering prices; (2) DRG/DIP hospital-payment reform changing which procedures get reimbursed and at what intensity (it dented cataract-surgery volumes for some spherical/aspheric IOLs in 2025); and (3) a weaker Chinese consumer pressuring discretionary aesthetics spend.

(Market caps are approximate peer-size references only, as of June 2026, and move daily.)

SECTION 6: INDUSTRY

Haohai sits at the intersection of three Chinese healthcare-demand stories.

Medical aesthetics is driven by rising disposable income, the normalization of cosmetic procedures, and a shift toward "light medical aesthetics" (injectables over surgery). The Chinese cosmetic/aesthetics market has been one of the faster-growing consumer-health categories, though 2025 demonstrated its cyclicality: a weaker consumer and intensifying price competition pulled HA filler revenue down across the sector. This is the most discretionary, most cyclical of Haohai's end-markets.

Ophthalmology is driven by demographics and disease prevalence: an aging population lifts cataract surgery volumes (driving OVD and IOL demand), while a national myopia epidemic among children drives OK-lens and myopia-control demand. The structural tailwind (more surgeries, more myopes) is strong; the structural headwind is policy - VBP compressing IOL prices and DRG/DIP reform altering procedure economics.

Orthopedics and anti-adhesion ride rising surgical volumes and an aging population with more osteoarthritis. Steady, less cyclical demand, again shadowed by the threat of VBP spreading to these categories.

Industry size and Haohai's place in the supply chain. Haohai is a domestic biomaterials manufacturer positioned as the local alternative to imported brands. The IOL market in China has historically been led by imports (Alcon, J&J, Bausch + Lomb, Zeiss, HOYA), and import substitution - domestic players taking share via cost and VBP - is the central supply-chain story; it cuts in Haohai's favour on volume but against it on price. In contact/IOL materials, through Contamac, Haohai is a global upstream supplier, an unusual position for a Chinese device company. Frost & Sullivan recognized Haohai with a "2025 Global Premium Hyaluronic Acid Technology Leadership Award," a third-party marker of its HA technical standing.

Regulation. The dominant industry force. Every flagship product needs NMPA Class III clearance. But the more consequential regulation now is reimbursement and procurement: VBP (centralized volume-based procurement) and DRG/DIP payment reform. These are not background risks - in 2025 they were the direct cause of falling ophthalmology revenue, as the November 2023 IOL procurement's second contract phase held prices down and DRG/DIP changes cut some cataract-procedure volumes.

Cyclicality. The aesthetics segment is consumer-cyclical; the medical segments (eye/ortho/surgical) are demographically driven and far less cyclical, but politically sensitive to procurement policy. The blended business is therefore moderately cyclical with a large policy-risk overlay.

SECTION 7: GROWTH TRIGGERS

Drawn from the five most recent reporting-period disclosures and the company's Investor Relations Activity Record. Because Haohai discloses via filings rather than transcribed calls, triggers are cited to the relevant report.

• Haimei Yuebai (4th-generation, lysine-cross-linked filler) volume ramp. Approved July 2024; management has repeatedly framed it as the key future driver of the aesthetics segment. (Repeated across the IR Activity Record, Aug 21 2024; reiterated through the FY2025 annual report, Mar 20 2026.)

  In the August 2024 investor-relations record, management positioned Yuebai as China's first organically (amino-acid) cross-linked HA filler with longer-lasting, safety-differentiated characteristics - the premium product it expects to "release volume" (放量) going forward.

• IOL cost re-engineering via the new hydrophobic molding process. Approved June 2023; management cites it as the means to protect IOL profitability under VBP price cuts. (Referenced in FY2024 and FY2025 annual disclosures.)

• Premium IOL mix shift to toric and multifocal lenses. Management's stated response to base-IOL price erosion is to move up the value ladder into astigmatism-correcting and multifocal designs. (FY2024 annual report, Mar 2025; restated FY2025 annual report, Mar 2026.)

• Ophthalmic pharmaceutical pipeline. Sodium-hyaluronate eye drops approved March 2024; a pipeline including bimatoprost, moxifloxacin, lidocaine gel and an artificial vitreous body is in development, broadening ophthalmology beyond devices. (FY2024 annual report.)

• Contact-lens-material expansion through Contamac. Continued development of next-generation gas-permeable materials (Optimum Infinite, FDA-cleared 2019) for OK lenses, scleral and soft lenses, supporting the global materials franchise. (Company materials, FY2024-FY2025 disclosures.)

• Maintained high capital return as a deliberate signal. The FY2025 annual report set a cash-dividend payout of ~90.5% of net profit, with management continuing buyback-and-cancellation of H-shares - an explicit commitment to returning capital even as earnings fell. (FY2025 annual report, Mar 20 2026.)

Note: these triggers are predominantly product-mix and policy-mitigation in nature rather than new-plant or new-customer wins; that itself characterizes where Haohai is in its cycle - defending and premiumizing, not expanding capacity.

SECTION 8: KEY RISKS

1. Volume-based procurement (VBP) compressing prices - already materializing. This is the central, high-probability risk. China's national IOL procurement (November 2023) entered the second phase of its two-year contract in 2025, holding selling prices down sharply; combined with DRG/DIP hospital-payment reform changing cataract-procedure economics, ophthalmology revenue fell in 2025. The mechanism is direct: win volume, lose price, and watch high-margin products de-rate. The live risk is VBP spreading to orthopedic viscosupplements and other categories where Haohai is the share leader - leadership becomes a liability when the government negotiates against your whole installed base.

The FY2025 annual report stated the IOL VBP had entered the second stage of its two-year agreement period and that intensifying competition - especially low-cost, low-price domestic lenses - posed a greater challenge to imported and premium products alike.

2. Controlling-shareholder regulatory and legal overhang - company-specific and serious. In May 2025 the CSRC opened an insider-trading case against Jiang Wei, the controlling shareholder and co-founder. In December 2025 the CSRC issued an administrative penalty: confiscation of ~RMB 4.71m of illegal gains plus a ~RMB 14.63m fine (total >RMB 19.3m) for insider trading and recommending securities trades to others. By May 2026, reporting indicated Jiang Wei had been released on bail, implying a criminal dimension. The company's position is that this is a personal matter, unrelated to Haohai's own stock, and that Jiang Wei is not involved in day-to-day management. The mechanism of harm here is governance and reputation, not operations: a founder-controller under criminal investigation creates headline risk, potential distraction, and a discount that overhangs the equity regardless of operating performance. Calibration: low operational probability, but a real and persistent governance/sentiment drag.

3. Aesthetics demand cyclicality and price competition - high-probability moderate drag. The growth-engine segment is consumer-discretionary. In 2025, HA filler revenue fell ~23% year-on-year as Chinese consumer demand softened and competitors cut prices. The mechanism: aesthetics is the highest-margin, most-watched segment, so weakness there hits both profit and the growth narrative. Management itself attributed the Q1 2026 revenue decline to insufficient domestic consumer demand and intensifying price competition pressuring high-margin product sales.

4. Stretched receivables / working capital. The Q3 2025 disclosure flagged accounts receivable at roughly 71% of trailing net profit, with performance described as marketing-driven. The mechanism: if hospital and distributor payment terms keep lengthening under fiscal pressure, cash conversion deteriorates and bad-debt risk rises even if reported revenue holds.

5. Single-molecule concentration and commoditization. Much of the business rests on hyaluronic acid across four uses. HA is widely produced; the moat is in cross-linking, registration, and channel, not the molecule. If a premium product (Yuebai) fails to differentiate clinically in the market's eyes, or if a "bun-face" safety scare hits HA fillers broadly, multiple segments feel it at once.

6. Premium-product execution risk. The growth story leans heavily on Haimei Yuebai ramping and on toric/multifocal IOLs taking share. If those launches under-deliver, there is no obvious second engine to offset VBP-driven base erosion.

SECTION 9: WALK THE TALK

The five reporting periods used:

1. Q1 2025 (ended 31 Mar 2025) - released ~25 Apr 2025
2. H1 2025 interim (ended 30 Jun 2025) - released ~23-25 Aug 2025
3. Q3 2025 (ended 30 Sep 2025) - released ~26 Oct 2025
4. FY2025 annual (ended 31 Dec 2025) - released 20 Mar 2026
5. Q1 2026 (ended 31 Mar 2026) - released 24 Apr 2026

(The most recent, Q1 2026, was released ~51 days before this report's date, comfortably inside the 90-day window.)

The honest summary: over this stretch, management's narrative held steady - "Yuebai will ramp, we will defend IOLs on cost and premiumize" - while the numbers deteriorated every quarter. That is the central credibility tension.

Entering 2025, the FY2024 annual report (released March 2025) showed a business that had roughly held the line - revenue up ~1.6%, net profit up ~1% - and management guided to continued growth, with the Yuebai filler and premium IOLs as the engines. The plan was coherent.

By Q1 2025, the first cracks: revenue slipped and net profit fell modestly year-on-year, with R&D spend cut ~25% - an early sign of belt-tightening that sat slightly uneasily against a "premiumize and innovate" narrative. Management framed it as transitional.

By H1 2025, the deterioration was undeniable: revenue down ~7.5% and net profit down ~10%. The Yuebai-led aesthetics story was now fighting a falling tide - filler revenue was heading toward a ~23% full-year decline. Management's message did not change; the results kept sliding.

Q3 2025 confirmed the trend (nine-month net profit down ~10.6%) and surfaced a new concern management had not foregrounded - accounts receivable at ~71% of net profit, and a business characterized as marketing-driven. The promise of disciplined, profitable growth was now visibly strained by working capital.

The FY2025 annual report (March 2026) delivered the full reckoning: revenue down ~8.3% and net profit down ~40%. The IOL VBP second-phase price cut and the aesthetics demand slump had done exactly what the risks predicted. Critically, management's response here is the most telling credibility data point: rather than cut the dividend to preserve cash, they raised the payout ratio to ~90.5% and continued buying back and cancelling H-shares. Whatever one thinks of the operating miss, they backed their capital-return commitment when it would have been easy to retreat.

Q1 2026 showed no inflection - revenue down ~7.6%, net profit down ~18.6% - with management again attributing the shortfall to weak domestic consumption and price competition.

Assessment. This is management that is consistent in narrative and consistently optimistic in framing, operating into a genuinely worsening external environment (VBP and a soft consumer) that it does not fully control. The forward promises - Yuebai ramp, IOL premiumization - were repeated faithfully across all five periods but have not yet shown up as growth; they have so far cushioned decline rather than driven gains. Two things temper the "overpromiser" read: management's explanations (VBP, consumer weakness) are externally verifiable and not excuses, and their walk on capital return (raising payout into a downturn, buyback-and-cancel) matched their talk precisely. The governance cloud over the controlling shareholder, however, is a separate and material strike against the "trustworthy stewards" case. Net: credible on capital allocation and candid on the macro/policy causes, but the operating turnaround they keep promising remains unproven, and the founder's CSRC penalty is a real blemish.

SECTION 10: SHAREHOLDER FRIENDLINESS INDEX

Dividends. Haohai has paid steadily and, notably, kept the absolute cash return roughly flat even as earnings fell. For FY2024 the company distributed a final dividend of RMB 6.00 per 10 shares (RMB 0.60/share) and, including the interim, total cash dividends representing ~54.9% of net profit (roughly RMB 230m). For FY2025 the total cash dividend (interim plus final, the final being RMB 4.00 per 10 shares) was RMB 227.17m, equal to ~90.5% of net profit - the payout ratio jumped sharply because profit fell ~40% while the absolute dividend was held near prior-year levels. In per-share terms total dividends were roughly RMB 0.98-1.00/share in both FY2024 and FY2025 - essentially flat. The >90% FY2025 payout is the standout: management chose to maintain the cash return rather than rebuild a buffer, which is shareholder-friendly on its face (though one should note the controlling family receives ~46% of every distribution - across 2019-2024 the founder couple reportedly received ~RMB 3.44bn in dividends, so generous payouts also enrich insiders). FY2023's exact DPS was not separately verified in this research.

Buybacks and dilution. Haohai ran a genuine, executed H-share repurchase. Under a general mandate approved at the 2024 AGM (29 May 2024), it bought back 612,600 H-shares between 5 December 2024 and 12 May 2025 for HK$15.39m (about 0.26% of total share capital), and then cancelled those shares on 28 July 2025, reducing total shares outstanding from 233,193,695 to 232,581,095. A separate A-share repurchase program was also active (e.g., ~169,800 A-shares cumulatively bought in January 2025). A fresh H-share buyback mandate was tabled for shareholder approval in April 2026. Per the MoatMap database, zero buybacks were recorded in the trailing ~90-day window (since 16 March 2026) - this reflects only that no repurchase fell in that recent window, not the multi-year history above. Net share count over three years has been flat-to-slightly-shrinking (cancellation of repurchased H-shares, no meaningful option dilution) - shareholders are not being diluted.

Verdict: Returns Capital - the company sustained near-flat absolute dividends into a 40% earnings drop (pushing payout to ~90.5%) and retires the shares it buys back, though the high payout disproportionately benefits the controlling family.

SECTION 11: INSIDER ACTIVITIES

Source: MoatMap cross-market disclosure database (HKEX Disclosure-of-Interests filings), the canonical source for recent Hong Kong insider dealing here (the HKEX DI portal is gated). Data current as of 2026-06-14. The "% O/S" figures below are evidently measured against the H-share class float (a minority of total shares), not total shares outstanding - so they overstate the economic stake relative to the full ~232.6m-share capital, and should be read as H-share-class percentages.

Buys - reading the signal. There is one genuine open-market purchase in the window: Tang Minjie's 5,000-share buy on 11 June 2026 at HK$16.668 (HK$83,340). In absolute terms this is small - a token, not a salary-scale conviction buy - so while directionally positive (a director adding at market), it is not a strong standalone signal and should not be over-read. No clustering of open-market buying occurred; the other two filings are not market purchases.

The two "Other" filings. Hou Yongtai's 8.4m-share and Tian Min's 10,189-share entries on 29 May 2026 are classified "Other," which at HKEX typically denotes deemed/associated interests or a disclosure-threshold trigger (e.g., a corporate action or reclassification around the AGM period) rather than an active open-market buy or sell. They should not be interpreted as conviction trades in either direction. Hou Yongtai's holding being ~24% of the H-share class indicates a substantial H-shareholder relationship rather than a routine director dealing.

Sells. No open-market insider sells appear in the trailing-12-month MoatMap window. Reason for the "Other" entries: not disclosed beyond the filing type; no estate, gift, or 10b5-1-equivalent context was available.

Net assessment. Insider activity is light and not clearly directional: one small director open-market buy and two non-trade "Other" disclosures, concentrated around the late-May AGM window. There is no insider selling, which is mildly reassuring, but there is also no cluster of meaningful buying that would constitute a bullish conviction signal. Read: neutral, with a faint positive tilt from the absence of selling and a small director purchase - not enough to outweigh the governance overhang from the controlling shareholder's CSRC penalty discussed in Section 8. Note also that this HKEX-DI feed does not capture the founders' A-share dealings, where the more consequential insider story (Jiang Wei's insider-trading case) sits.

SECTION 12: SCENARIOS

Bull case. The Chinese consumer recovers and aesthetics demand turns. Haimei Yuebai - the differentiated, lysine-cross-linked, longer-lasting filler - finally does what management has promised for two years and takes premium share from Imeik and the imports, restoring growth and mix to the aesthetics engine. On the eye side, the worst of the IOL price reset is behind the company; the cost-down molding process protects margins on base lenses while toric and multifocal IOLs and the new eye-drop pipeline carry the average selling price back up, so ophthalmology stabilizes and grows again. Orthopedics and anti-adhesion keep generating cash without VBP hitting them. The founder's legal cloud resolves with the personal penalty already paid and no spillover into the company, and the governance discount fades. Management's stubborn commitment to a ~90% payout and share cancellation, sustained through the downturn, looks in hindsight like confidence that was rewarded. The story becomes: a diversified, cash-generative biomaterials leader that defended its base through a brutal policy-and-consumer squeeze and came out the other side with a premium aesthetics product hitting its stride.

Base case. The most likely path is more of what the last five quarters showed: a business defending, not growing. VBP and DRG/DIP keep a lid on ophthalmology pricing; aesthetics stays competitive and consumer-soft, with Yuebai cushioning rather than reversing the filler decline. Haohai holds its leading shares in OVDs, joint injections, and anti-adhesion, throws off cash, and keeps returning most of it as dividends and small buyback-and-cancellations. Revenue and profit stay under pressure or grind sideways while management executes the same playbook - premiumize, cut costs, market hard. The founder's case stays a contained personal matter and a persistent sentiment discount rather than an operating problem. It is a steady, policy-shadowed, capital-returning compounder-that-isn't-compounding - reliable cash, limited growth.

Bear case. VBP spreads from IOLs into orthopedic viscosupplements and anti-adhesion, attacking the very segments where Haohai's market leadership is largest - turning its strongest moats into its biggest price-compression exposures simultaneously. The aesthetics downturn proves structural rather than cyclical: Yuebai never differentiates enough to command its premium, Imeik and Bloomage keep winning, and filler revenue keeps falling. Stretched receivables (already ~71% of net profit) convert into bad debts as hospitals and distributors strain under fiscal pressure, hitting reported cash flow. The high dividend payout, maintained out of habit into falling earnings, eventually has to be cut, breaking the one part of the story that was working and removing the floor under the shares. And the governance overhang worsens - the founder's legal situation escalates or implicates the company, distracting management and deepening the discount. In this scenario Haohai is a single-molecule, policy-exposed device maker whose three "cash cow" segments all get procured down to thin margins at once, with no growth engine to replace them.

A few framing notes on the data: segment mix and the 50/47/29% share figures are approximate, drawn from company disclosures and 2024 annual-report market-share claims; the growth-trajectory chart shows directional YoY percentages (not absolute revenue) consistent with the no-financials rule; and the dividend chart carries the two years that were cleanly sourced.

Sources:

• Haohai 2024 annual report summary - Yicai Global
• Haohai Q1 2026 unaudited update - TipRanks
• FY2025 results / segment coverage - QQ News (Q3 2025 analysis)
• Haohai hyaluronic acid & ophthalmology analysis - Moomoo
• H1 2025 semi-annual report summary - Shanghai Securities News
• FY2025 dividend distribution plan - Sina Finance
• H-share buyback cancellation of 612,600 shares - Sina Finance
• A-share buyback January 2025 - Sina Finance
• Controlling shareholder Jiang Wei CSRC insider-trading case - 21jingji
• Jiang Wei CSRC penalty >RMB 19.3m - NBD / Meirijingji
• Jiang Wei released on bail update - Sina Finance
• Founding history - Pestel-analysis / 3Healthcare
• STAR Market record IPO 2019 - Yicai Global
• Contamac acquisition & lens materials - 3Healthcare news
• Hyaluronic acid competitive landscape (Bloomage, Imeik) - China Daily
• Haimei Yuebai 4th-gen filler approval - Songjiang Gov / ByDrug
• Frost & Sullivan 2025 HA technology award - Cantech Letter
• Insider transactions: MoatMap cross-market disclosure database (HKEX DI filings), as of 2026-06-14.

A research note: I was unable to render the official HKEX FY2025 results PDF (binary/encoded), so the FY2025 figures used for direction-only context come from corroborating Chinese financial-press coverage of that filing; segment mix percentages are approximations derived from disclosed sub-segment figures.